Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 5.1
(0.99%)
CNY 5.1
(0.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.1 Billion CNY | -80.45% |
| 2022 | 5.59 Billion CNY | 109.39% |
| 2021 | 2.67 Billion CNY | 97.34% |
| 2020 | 1.35 Billion CNY | 85.7% |
| 2019 | 729.39 Million CNY | 25.68% |
| 2018 | 580.35 Million CNY | 21.14% |
| 2017 | 479.08 Million CNY | 20.28% |
| 2016 | 398.3 Million CNY | 15.51% |
| 2015 | 344.83 Million CNY | 30.58% |
| 2014 | 264.08 Million CNY | 44.53% |
| 2013 | 182.71 Million CNY | 31.44% |
| 2012 | 139.01 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 225.78 Million CNY | 24.53% |
| 2024 Q1 | 181.3 Million CNY | -27.53% |
| 2024 Q3 | 197.61 Million CNY | -10.82% |
| 2023 Q4 | 250.18 Million CNY | 2.54% |
| 2023 Q3 | 243.99 Million CNY | -19.88% |
| 2023 FY | 1.09 Billion CNY | -80.45% |
| 2023 Q2 | 304.52 Million CNY | 0.8% |
| 2023 Q1 | 302.11 Million CNY | -77.43% |
| 2022 Q4 | 1.33 Billion CNY | -5.48% |
| 2022 Q2 | 1.33 Billion CNY | -11.84% |
| 2022 Q1 | 1.51 Billion CNY | 121.71% |
| 2022 FY | 5.59 Billion CNY | 109.39% |
| 2022 Q3 | 1.41 Billion CNY | 6.33% |
| 2021 Q4 | 681.38 Million CNY | -1.68% |
| 2021 Q2 | 689.16 Million CNY | 13.08% |
| 2021 Q3 | 693 Million CNY | 0.56% |
| 2021 FY | 2.67 Billion CNY | 97.34% |
| 2021 Q1 | 609.47 Million CNY | 39.25% |
| 2020 FY | 1.35 Billion CNY | 85.7% |
| 2020 Q3 | 411.28 Million CNY | 15.59% |
| 2020 Q1 | 149.71 Million CNY | -29.28% |
| 2020 Q4 | 437.67 Million CNY | 6.42% |
| 2020 Q2 | 355.82 Million CNY | 137.67% |
| 2019 Q2 | 180.2 Million CNY | 31.67% |
| 2019 Q4 | 211.71 Million CNY | 5.53% |
| 2019 Q1 | 136.85 Million CNY | -22.04% |
| 2019 FY | 729.39 Million CNY | 25.68% |
| 2019 Q3 | 200.61 Million CNY | 11.33% |
| 2018 Q1 | 106.93 Million CNY | -25.32% |
| 2018 FY | 580.35 Million CNY | 21.14% |
| 2018 Q4 | 175.54 Million CNY | 13.11% |
| 2018 Q3 | 155.2 Million CNY | 8.78% |
| 2018 Q2 | 142.67 Million CNY | 33.42% |
| 2017 FY | 479.08 Million CNY | 20.28% |
| 2017 Q3 | 125.58 Million CNY | 1.75% |
| 2017 Q4 | 143.19 Million CNY | 14.03% |
| 2017 Q1 | 86.89 Million CNY | -26.76% |
| 2017 Q2 | 123.41 Million CNY | 42.04% |
| 2016 Q3 | 101.68 Million CNY | -1.99% |
| 2016 FY | 398.3 Million CNY | 15.51% |
| 2016 Q2 | 103.74 Million CNY | 39.73% |
| 2016 Q1 | 74.24 Million CNY | 0.0% |
| 2016 Q4 | 118.63 Million CNY | 16.68% |
| 2015 FY | 344.83 Million CNY | 30.58% |
| 2014 FY | 264.08 Million CNY | 44.53% |
| 2013 FY | 182.71 Million CNY | 31.44% |
| 2012 FY | 139.01 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 91.763% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion CNY | 85.043% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | 18.988% |
| Beijing Strong Biotechnologies, Inc. | 1.74 Billion CNY | 36.585% |
| Medicalsystem Biotechnology Co., Ltd. | 1.88 Billion CNY | 41.435% |
| Maccura Biotechnology Co.Ltd | 2.89 Billion CNY | 61.86% |
| Guangzhou Wondfo Biotech Co.,Ltd | 2.76 Billion CNY | 60.055% |
| BGI Genomics Co., Ltd. | 4.34 Billion CNY | 74.608% |
| Amoy Diagnostics Co., Ltd. | 1.03 Billion CNY | -6.317% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1.67 Billion CNY | 34.038% |